Icagen, based in Research Triangle Park, N.C., focuses on the discovery, development and commercialization of orally-administered, small-molecule drugs that modulate ion channel targets.
Pfizer previously owned 11 percent of Icagen and had invested about $56 million in the company.
Related Articles on Pfizer:
Pfizer Reports “Potentially Improper Payments” Made Outside U.S.
Global Pain Medication Sales Rise 8.9% Since 2005
Study: Lyrica Pain Drug From Pfizer Effective for Spinal Pain
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
